Publications by authors named "Takeshi Kashimura"

Background: Collaboration between cardiologists and oncologists was recommended as part of Japan's Basic Plan to Promote Disease Control Programs in 2023. We evaluated the extent of this collaboration regarding anthracycline-related cardiomyopathy (ARCM).

Methods And Results: Self-administered questionnaires on ARCM were distributed to all cardiologists and leading oncologists in hospitals across the Niigata Prefecture.

View Article and Find Full Text PDF

Background: Polypharmacy, driven by guideline-directed medical therapy (GDMT) and medications for comorbidities, including potentially inappropriate medications (PIMs), is common in older adults with heart failure (HF). Although medication profiles affect survival, the effects of frailty and disability status remain underexplored.

Methods And Results: This retrospective study assessed polypharmacy (≥5 medications), the use of GDMT, and PIMs based on the Beers Criteria.

View Article and Find Full Text PDF

Aim: The number of patients with heart failure with disability and the use of Long-Term Care Insurance (LTCI) has been increasing in the Japanese aging society. This study investigated the main causes of LTCI demands for better care management.

Methods: We carried out a retrospective study including patients with heart failure with reduced ejection fraction in seven hospitals in Niigata City from 2011 to 2016.

View Article and Find Full Text PDF

Unlabelled: Left main compression syndrome (LMCS) is a disease in which the ostium of the left main coronary artery is compressed between a dilated pulmonary artery and the sinus of Valsalva associated with pulmonary hypertension (PH). The major etiology of LMCS is secondary PH due to congenital heart disease. However, no reports exist regarding LMCS caused by PH due to peripheral pulmonary artery stenosis complicated with moyamoya disease (MMD).

View Article and Find Full Text PDF

Background: In 2023, collaboration between cardiologists and oncologists was recommended as part of Japan's Basic Plan to Promote Disease Control Programs for both cancer and cardiovascular diseases. This study explores the extent of this collaboration in Niigata Prefecture.

Methods And Results: Self-administered questionnaires about immune checkpoint inhibitor-associated myocarditis (ICIAM) and anthracycline-related cardiomyopathy (ARCM) were distributed to all cardiologists and leading oncologists in hospitals across the Prefecture, of whom 124 cardiologists and 41 oncologists across 29 hospitals responded.

View Article and Find Full Text PDF

Background: Approximately 10% of hypertrophic cardiomyopathy (HCM) patients have left ventricular systolic dysfunction (end-stage HCM) leading to severe heart-failure; however, risk stratification to identify patients at risk of progressing to end-stage HCM remains insufficient.

Objectives: In this study, the authors sought to elucidate whether the coexistence of other cardiovascular disease (CVD)-related variants is associated with progression to end-stage HCM in patients with HCM harboring pathogenic or likely pathogenic (P/LP) sarcomeric variants.

Methods: The authors performed genetic analysis of 83 CVD-related genes in HCM patients from a Japanese multicenter cohort.

View Article and Find Full Text PDF
Article Synopsis
  • Clonal hematopoiesis of indeterminate potential (CHIP) is shown to worsen outcomes in patients with nonischemic dilated cardiomyopathy (DCM) despite being well-known for its negative impacts on atherosclerotic disease.
  • Researchers analyzed 198 DCM patients using advanced genetic sequencing to find both germline mutations linked to cardiomyopathy and somatic mutations in CHIP driver genes, discovering 25 CHIP mutations in 22 patients.
  • The study concluded that CHIP is an independent risk factor for cardiac issues in DCM, contributing to worsened heart function and structural damage, and that genetic mutations can help predict patient prognosis.
View Article and Find Full Text PDF

Lowering mean pulmonary arterial pressure (mPAP) without reducing cardiac output is essential in treating pulmonary hypertension (PH). Isosorbide dinitrate (ISDN) potentially achieves this in post-capillary PH but can decrease cardiac output and blood pressure (BP), especially in pre-capillary PH. However, post-capillary PH and pre-capillary PH can overlap, and their clear discrimination is difficult.

View Article and Find Full Text PDF

Background: Trastuzumab has improved breast cancer (BC) prognosis and reduced anthracycline use. However, the characteristic changes of anthracycline-related cardiomyopathy (ARCM) in patients with BC remain unclear. We aimed to update our understanding of ARCM in the trastuzumab era.

View Article and Find Full Text PDF

Continuous intravenous adenosine triphosphate (ATP) administration is the standard method for inducing maximal hyperemia in fractional flow reserve (FFR) measurements. Several cases have demonstrated fluctuations in the ratio of mean distal coronary pressure to mean arterial pressure (Pd/Pa) value during ATP infusion, which raised our suspicions of FFR value inaccuracy. This study aimed to investigate our hypothesis that Pd/Pa fluctuations may indicate inaccurate FFR measurements caused by insufficient hyperemia.

View Article and Find Full Text PDF

Background: Pulsus alternans has been considered a sign of poor prognosis in patients undergoing treatments for heart failure. However, it may be overlooked in patients with intra-aortic balloon pumps (IABPs). The use of IABP and ivabradine for a β-blocker introduction in a patient with dilated cardiomyopathy (DCM) and pulsus alternans and its consequence have never been reported.

View Article and Find Full Text PDF

Unlabelled: A 45-year-old woman with no medical history underwent pacemaker implantation for a symptomatic complete atrioventricular block. On day 6, she noticed diplopia and then fever, general malaise, and elevation of serum creatinine kinase (CK). She was transferred to our hospital on day 21.

View Article and Find Full Text PDF

Background: Although guideline-directed medical therapy (GDMT), including β-blockers, angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs), improves survival and quality of life, most patients with heart failure with reduced (HFrEF) and mildly reduced (HFmrEF) ejection fraction are treated with inadequate medications. We investigated the prescription patterns of GDMT in elderly patients with HFrEF and HFmrEF and their characteristics, including the certification of long-term care insurance (LTCI), which represents frailty and disability.

Methods and results: This retrospective cross-sectional study analyzed 1,296 elderly patients with symptomatic HFrEF and HFmrEF with diuretic use (median age 78 years; 63.

View Article and Find Full Text PDF

Immunosuppressive therapy with prednisolone (PSL) is the first-line treatment for cardiac sarcoidosis (CS), and F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) is used to evaluate its efficacy to guide treatment. However, the appropriate timing of FDG-PET in CS remains unknown. This single-center, retrospective, observational study included 15 consecutive CS patients who underwent 3 serial FDG-PET scans (at baseline, in the early phase [1-2 months after PSL introduction], and in the late phase [≥ 5 months after PSL introduction with a maintenance dose of PSL]).

View Article and Find Full Text PDF

Objective Spontaneous mechanical alternans (MA), or pulsus alternans, has been observed in heart failure patients with hypertension or tachycardia for 150 years and is considered a sign of a poor prognosis. However, in some dilated cardiomyopathy (DCM) patients with MA, optimal medical therapy (OMT) brings left ventricular reverse remodeling (LVRR), a preferable prognostic indicator. This study examined the probability of LVRR in DCM patients with spontaneous MA and whether or not LVRR can be predicted by the baseline blood pressure or heart rate.

View Article and Find Full Text PDF

Background: In patients with chronic heart failure (CHF) and type 2 diabetes (T2D), sodium-glucose cotransporter-2 (SGLT2) inhibition improves cardiorenal outcomes, but details of the effects on distinct subsets of body fluid volume remain incomplete.

Methods: This was a post hoc analysis of patients with CHF and T2D in the CANDLE trial (UMIN000017669), an investigator-initiated, multi-center, randomized open-label trial that compared the effect of canagliflozin (100 mg, n = 113) with glimepiride (starting dose: 0.5 mg, n = 120) on changes in N-terminal pro-brain natriuretic peptide.

View Article and Find Full Text PDF

Antimitochondrial antibodies (AMA) are serum autoantibodies specific to primary biliary cholangitis and are linked to myopathy and myocardial damage; however, the presence of AMA as a risk factor for ventricular tachyarrhythmias (VTs) has remained unknown. This study aimed to elucidate whether the presence of AMA-related noncardiac diseases indicates VTs risk.This cohort study enrolled 1,613 patients (883 females) who underwent AMA testing to assess noncardiac diseases.

View Article and Find Full Text PDF

Since permanent inferior vena cava (IVC) filters increase deep vein thrombosis (DVT), filter retrieval should be performed as possible. Despite the guideline recommendation, IVC filters are not always retrieved in clinical practice. To date, many patients with not-retrieval IVC filters have been prescribed anticoagulant therapy, but the long-term prognosis, including venous thromboembolism (VTE) and bleeding events, remains unknown.

View Article and Find Full Text PDF
Article Synopsis
  • Immunoglobulin-G4-related disease (IgG4-RD) is a rare inflammatory disorder affecting multiple organs, with unclear treatment approaches for coronary artery involvement.
  • A case report describes mass lesions around the coronary arteries, specifically showing moderate stenosis in the right coronary artery (RCA) and a fractional flow reserve (FFR) measurement of 0.76.
  • Following steroid treatment, both the mass lesions and FFR improved, rising from 0.76 to 0.86, indicating that steroids may be an effective therapy for managing coronary artery issues related to IgG4-RD.
View Article and Find Full Text PDF